BioAtla BCAB Stock
BioAtla Price Chart
BioAtla BCAB Financial and Trading Overview
| BioAtla stock price | 3.13 USD |
| Previous Close | 3.55 USD |
| Open | 3.55 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 800 |
| Day's Range | 3.45 - 3.75 USD |
| 52 Week Range | 2.24 - 12.15 USD |
| Volume | 967K USD |
| Avg. Volume | 491.44K USD |
| Market Cap | 182.81M USD |
| Beta (5Y Monthly) | 0.250796 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.4 USD |
BCAB Valuation Measures
| Enterprise Value | -19859318 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.51417 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.1388551 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.178 |
Trading Information
BioAtla Stock Price History
| Beta (5Y Monthly) | 0.250796 |
| 52-Week Change | 43.29% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.15 USD |
| 52 Week Low | 2.24 USD |
| 50-Day Moving Average | 3.48 USD |
| 200-Day Moving Average | 5.58 USD |
BCAB Share Statistics
| Avg. Volume (3 month) | 491.44K USD |
| Avg. Daily Volume (10-Days) | 435.99K USD |
| Shares Outstanding | 47.67M |
| Float | 28.71M |
| Short Ratio | 11.31 |
| % Held by Insiders | 14.07% |
| % Held by Institutions | 71.37% |
| Shares Short | 3.61M |
| Short % of Float | 8.26% |
| Short % of Shares Outstanding | 7.58% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.37% |
| Return on Equity (ttm) | -63.31% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -79347000 USD |
| EBITDA | -111545000 USD |
| Net Income Avi to Common (ttm) | -109688000 USD |
| Diluted EPS (ttm) | -2.52 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 192.69M USD |
| Total Cash Per Share (mrq) | 4.04 USD |
| Total Debt (mrq) | 3.61M USD |
| Total Debt/Equity (mrq) | 2.31 USD |
| Current Ratio (mrq) | 7.607 |
| Book Value Per Share (mrq) | 3.284 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -87938000 USD |
| Levered Free Cash Flow (ttm) | -48518500 USD |
Profile of BioAtla
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 11085 Torreyana Road |
| ZIP | 92121 |
| Phone | 858 558 0708 |
| Website | https://www.bioatla.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 66 |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Q&A For BioAtla Stock
What is a current BCAB stock price?
BioAtla BCAB stock price today per share is 3.13 USD.
How to purchase BioAtla stock?
You can buy BCAB shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioAtla?
The stock symbol or ticker of BioAtla is BCAB.
Which industry does the BioAtla company belong to?
The BioAtla industry is Biotechnology.
How many shares does BioAtla have in circulation?
The max supply of BioAtla shares is 48.1M.
What is BioAtla Price to Earnings Ratio (PE Ratio)?
BioAtla PE Ratio is now.
What was BioAtla earnings per share over the trailing 12 months (TTM)?
BioAtla EPS is -2.58 USD over the trailing 12 months.
Which sector does the BioAtla company belong to?
The BioAtla sector is Healthcare.
BioAtla BCAB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}